Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 2/20 | 0.38 |
| ▸ | PIK3R2 | O00459 | 2/20 | 0.38 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.38 |
| ▸ | PIK3CB | P42338 | 2/20 | 0.38 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.38 |
| ▸ | PIK3R5 | Q8WYR1 | 2/20 | 0.38 |
| ▸ | PIK3R3 | Q92569 | 2/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.36 |
| ▸ | HTR2A | P28223 | 1/20 | 0.36 |
| ▸ | HTR2C | P28335 | 1/20 | 0.36 |
| ▸ | HTR2B | P41595 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 3/20 | 0.36 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.35 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.34 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5337905 | 0.79 | CNR1 (0.43) | PIK3CDPIK3R2PIK3CAPIK3CBPIK3CG | |
| SCHEMBL5341653 | 0.76 | CYP1A2 (0.41) | CYP1A2HIF1AKMT2APTGS1PTGS2 | |
| SCHEMBL29042749 | 0.69 | MAPT (0.44) | CYP1A2KMT2AMAPTSMN1; SMN2GABRA1 | |
| SCHEMBL5343755 | 0.68 | CNR1 (0.48) | CYP1A2HIF1AIDO1TDO2LMNA | |
| SCHEMBL5341646 | 0.68 | CNR1 (0.48) | IDO1TDO2LMNA | |
| SCHEMBL5344766 | 0.64 | CNR1 (0.44) | CYP1A2HIF1AKMT2APTGS1PTGS2 | |
| SCHEMBL8132350 | 0.63 | PTGS2 (0.59) | KMT2AHTR2AHTR2CHTR2BPTGS1 | |
| SCHEMBL28691202 | 0.63 | PTGS2 (0.59) | KMT2AHTR2AHTR2CHTR2BPTGS1 | |
| SCHEMBL1475759 | 0.63 | HTR2A (0.82) | HTR2AHTR2CHTR2BPTGS1PTGS2 | |
| SCHEMBL1475799 | 0.63 | HTR2A (0.82) | HTR2AHTR2CHTR2BPTGS1PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7230024-B2 | Cannabinoid receptor ligands and uses thereof | PFIZER INC (US) | 2007-06-12 | — | — | US | claimed |
| US-20060205948-A1 | Cannabinoid receptor ligands and uses thereof | PFIZER INC | 2006-09-14 | — | — | US | claimed |
| US-20040214855-A1 | Cannabinoid receptor ligands and uses thereof | PFIZER INC | 2004-10-28 | — | — | US | claimed |
| US-7241788-B2 | Cannabinoid receptor ligands and uses thereof | PFIZER INC. (US) | 2007-07-10 | — | — | US | disclosed |
| US-7230024-B2 | Cannabinoid receptor ligands and uses thereof | PFIZER INC (US) | 2007-06-12 | — | — | US | disclosed |
| US-7145012-B2 | Cannabinoid receptor ligands and uses thereof | PFIZER INC. (US) | 2006-12-05 | — | — | US | disclosed |
| US-20060205948-A1 | Cannabinoid receptor ligands and uses thereof | PFIZER INC | 2006-09-14 | — | — | US | disclosed |
| US-20060205720-A1 | Cannabinoid receptor ligands and uses thereof | PFIZER INC | 2006-09-14 | — | — | US | disclosed |
| EP-1622909-A1 | CANNABINOID RECEPTOR LIGANDS AND USES THEREOF | Pfizer Products Inc. (US) | 2006-02-08 | — | — | EP | disclosed |
| WO-2004094429-A1 | CANNABINOID RECEPTOR LIGANDS AND USES THEREOF | PFIZER PRODUCTS INC. (US) | 2004-11-04 | — | — | WO | disclosed |
| US-20040214855-A1 | Cannabinoid receptor ligands and uses thereof | PFIZER INC | 2004-10-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060205720-A1 | Cannabinoid receptor ligands and uses thereof | CNR2, CNR1, GPR18 | PIK3CD 1617/4885PIK3R2 782/4885PIK3CA 2210/4885 |
| US-20060205948-A1 | Cannabinoid receptor ligands and uses thereof | CNR2, CNR1, GPR18 | PIK3CD 1617/4885PIK3R2 782/4885PIK3CA 2210/4885 |
| US-20040214855-A1 | Cannabinoid receptor ligands and uses thereof | CNR1, CNR2, GPR18 | PIK3CD 1593/4885PIK3R2 838/4885PIK3CA 2120/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.